Top Markets
#1 Black Phoenix Black Phoenix +820.83%
#2 Tutorial Tutorial +25.27%
#3 Beam Beam +25.04%
#4 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +24.53%
#5 MiL.k Alliance MiL.k Alliance +20.24%
#6 SAFEcoin SAFEcoin +18.55%
#7 Bless Bless +18.33%
#8 Wrapped STX (Velar) Wrapped STX (Velar) +15.85%
#9 THORChain THORChain +15.63%
#10 Magma Finance Magma Finance +15.39%
Coin of the day
Black Phoenix Black Phoenix
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Lin BioScience, Inc. Lin BioScience, Inc.

Lin BioScience, Inc.

6696
Kedudukan dalam Saham #5731
Lin BioScience, Inc. is an innovative biopharmaceutical company focused on... Lin BioScience, Inc. is an innovative biopharmaceutical company focused on developing novel therapies across oncology, ophthalmology, and metabolic diseases. Its robust pipeline includes LBS-008, an orally administered treatment currently in Phase 3 clinical trials for adolescent Stargardt disease (STGD1) and Phase 2/3 trials for dry age-related macular degeneration (Dry AMD), both aimed at evaluating its safety and effectiveness. Other key candidates are LBS-007, a natural non-ATP CDC7 inhibitor designed to combat various cancers; LBS-002, an anti-tubulin compound targeting primary and metastatic brain tumors; and LBS-009, an oral medication for non-alcoholic fatty liver disease and Type 2 diabetes. The company is headquartered in Taipei, Taiwan.
Harga Saham
$29.86
Disegerakkan terakhir: 2026-08-19
Modal Pasaran
$2.48B
Perubahan (1 hari)
4.92%
Perubahan (1 tahun)
502.82%
Negara
TW
Perdagangan Lin BioScience, Inc. (6696)

Kategori

Healthcare
Hasil untuk Lin BioScience, Inc. (6696)
Hasil pada Aug 2026 TTM: 0
Menurut laporan kewangan terkini daripada Lin BioScience, Inc., hasil semasa syarikat (TTM) ialah 0. Pada tahun 2026, syarikat memperoleh hasil sebanyak 0 sama dengan hasil pada tahun 2026 iaitu 0. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Lin BioScience, Inc. dari 2026 hingga 2026
Hasil pada akhir setiap tahun
Tahun Hasil Ubah
Tidak cukup data untuk tarikh yang disediakan.
Hasil untuk syarikat atau pesaing serupa
Syarikat Hasil Perbezaan Hasil Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH